Atlas-based measures of left ventricular shape may improve characterization of adverse remodeling in anthracycline-exposed childhood cancer survivors: a cross-sectional imaging study

Table 1 Subject Characteristics

Characteristic	Survivor-Reference Comparison			Survivor Cohort Compared By Cumulative Anthracycline Dose
Characteristic	Reference Population (N = 1991)^a	Survivor Cohort (N = 20)^a	P^†	Low-Dose (N = 10)^a	High-Dose (N = 10)^a	P^†
*Demographics*
Age at Imaging, y	61.5 (10.2)	38.2 (6.3)	< 0.001	38.6 (6.6)	37.8 (6.3)	0.774
Sex
Male	957 (48%)	10 (50%)	0.863	5 (50%)	5 (50%)	1.00
Female	1034 (52%)	10 (50%)	0.863	5 (50%)	5 (50%)	1.00
Ethnicity
White/Non- Hispanic	739 (37%)	6 (30%)	< 0.001	2 (20%)	4 (40%)	0.329
Hispanic	491 (25%)	14 (70%)		8 (80%)	6 (60%)
Black/African American	405 (20%)	0 (0%)		0 (0%)	0 (0%)
Chinese	356 (18%)	0 (0%)		0 (0%)	0 (0%)
*Cancer*
Cancer Type
Leukemia	–	7 (35%)	–	4 (40%)	3 (30%)	0.129
Lymphoma	–	7 (35%)		5 (50%)	2 (20%)
Sarcoma	–	6 (30%)		1 (10%)	5 (50%)
Age at Diagnosis, y	–	14.9 (5.7)	–	13.5 (6.5)	16.4 (4.5)	0.271
Anthracycline Dose, mg/m²	–	255 (175, 368)	–	175 (100, 210)	368 (360, 450)	< 0.001
*Cardiac*
Body Mass Index	27.8 (5.1)	29.1 (6.8)	0.251	32.2 (5.5)	25.9 (6.7)	0.033
Hypertension^b	856 (43%)	5 (25%)	0.106	2 (20%)	3 (30%)	0.606
Heart Failure	0 (0%)	1 (5%)	0.010^\|\|	0 (0%)	1 (10%)	0.305

^aFor each group, the table depicts number (%) for categorical variables and mean (standard deviation) for continuous variables, except for anthracycline dosage, where the median (interquartile range) is shown
^bHypertension is defined as systolic blood pressure ≥ 140, diastolic blood pressure ≥ 90, or treatment with anti-hypertensive medication
† P-values for categorical variables are derived from Pearson’s chi squared tests. P-values for continuous variables are derived from two-sample T tests, except the p-value for anthracycline dose, which was derived from a Pearson’s chi-squared nonparametric equality of medians test
|| P-value derived from a Fisher’s exact test due to small numbers in each subgroup

ISSN: 2057-3804